Stocks · News reference
Truist Securities analyst Richard Newitter maintains SI-BONE (NASDAQ:SIBN) with a Buy and raises the price target from $23 to $25.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
SI-BONE, Inc. (NASDAQ:SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance
Filed: 2026-09-11 AccNo: 0001459839-26-000076 Size: 197 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
UBS analyst Patrick Wood maintains SI-BONE (NASDAQ:SIBN) with a Buy and raises the price target from $24 to $25.